Camurus Full Year 2024 Earnings: EPS Beats Expectations

Camurus (STO:CAMX) Full Year 2024 Results

Key Financial Results

• Revenue: kr1.87b (up 8.8% from FY 2023).
• Net income: kr428.4m (flat on FY 2023).
• Profit margin: 23% (down from 25% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: kr7.39 (down from kr7.78 in FY 2023).

We check all companies for important risks. See what we found for Camurus in our free report.

CAMX Products In Clinical Trials

• Phase I: 4.
• Phase II: 3.
• Phase III: 3.

CAMX Post-Clinical Trial Products

• Pre-registration: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Camurus EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.4%.

The primary driver behind last 12 months revenue was the Australia segment contributing a total revenue of kr535.6m (29% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to kr683.6m (52% of total expenses). Explore how CAMX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Sweden.

Performance of the Swedish Pharmaceuticals industry.

The company's shares are up 7.1% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Camurus' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.